Organogenesis Holdings Inc. (ORGO)


Stock Price Forecast

April 23, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Organogenesis Holdings Inc. chart...

About the Company

We do not have any company description for Organogenesis Holdings Inc. at the moment.

Sector

Life Sciences

Industry

Pharmaceutical Preparations

Employees

1073

Exchange

Nasdaq

$433M

Total Revenue

1K

Employees

$391M

Market Capitalization

54.26

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ORGO News

ORGO Organogenesis Holdings Inc.

1d ago, source: Seeking Alpha

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the ...

Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2023 Earnings Call Transcript

1mon ago, source: InvestingChannel on MSN

Organogenesis Holdings Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see ...

Organogenesis Holdings Inc Class A

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

21d ago, source: Business Insider

CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization ...

Organogenesis Holdings Inc. Cl A

5d ago, source: Wall Street Journal

1 Day ORGO 1.40% DJIA 0.56% Russell 2K 0.24% Health Care/Life Sciences -1.10% ...

Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance

1mon ago, source: Stockhouse

Gillheeney, Sr., President and Chief Executive Officer of Organogenesis. "Despite the expected operating environment challenges, we delivered revenues within the lower end of our guidance. Looking ...

Buy Rating Affirmed for Organogenesis Holdings Amid Stable Product Pricing and Positive Market Dynamics

1mon ago, source: Business Insider

Organogenesis Holdings (ORGO) Company Description: Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product ...

Organogenesis Holdings Inc - Ordinary Shares - Class A

20d ago, source: U.S. News & World Report

Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and ...

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

21d ago, source: Stockhouse

CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of ...

Organogenesis Holdings Inc.: Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

1mon ago, source: Finanznachrichten

CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...